Assembly Biosciences, Inc. Increase (Decrease) in Other Accrued Liabilities
Assembly Biosciences, Inc. (ASMB) reported Increase (Decrease) in Other Accrued Liabilities of -$4.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2026-08-13
- Assembly Biosciences, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2026-06-30 was $678.00K, a 38.64% decline year-over-year.
- Assembly Biosciences, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2026-03-31 was -$5.08M.
- Assembly Biosciences, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2025-12-31 was $2.02M, a 3.62% decline year-over-year.
- Assembly Biosciences, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2025-09-30 was $2.32M, a 97.03% increase year-over-year.
- Assembly Biosciences, Inc. increase (decrease) in other accrued liabilities for fiscal 2025 was $887.00K, a 20.66% decline from fiscal 2024.
- Assembly Biosciences, Inc. increase (decrease) in other accrued liabilities for fiscal 2024 was $1.12M.
- Assembly Biosciences, Inc. increase (decrease) in other accrued liabilities for fiscal 2023 was -$1.57M, a 443.01% decline from fiscal 2022.
- Assembly Biosciences, Inc. increase (decrease) in other accrued liabilities for fiscal 2022 was $458.00K.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 6 month | Increase (Decrease) in Other Accrued Liabilities 9 month | Increase (Decrease) in Other Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $678.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$4.41M 10-Q · filed 2026-08-13 | -$2.39M derived: sum of 3 quarters · filed 2026-08-13 | -$65.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$5.08M 10-Q · filed 2026-05-07 | -$3.06M derived: sum of 2 quarters · filed 2026-05-07 | -$743.00K derived: sum of 3 quarters · filed 2026-05-07 | $362.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $4.34M derived: sum of 2 quarters · filed 2026-03-19 | $5.45M derived: sum of 3 quarters · filed 2026-08-13 | $887.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $2.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $3.43M derived: sum of 2 quarters · filed 2026-08-13 | -$1.13M 10-Q · filed 2025-11-10 | $963.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$3.46M 10-Q · filed 2026-08-13 | -$1.36M derived: sum of 3 quarters · filed 2026-08-13 | -$180.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$4.56M 10-Q · filed 2026-05-07 | -$2.46M derived: sum of 2 quarters · filed 2026-05-07 | -$1.28M derived: sum of 3 quarters · filed 2026-05-07 | $251.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $3.27M derived: sum of 2 quarters · filed 2026-03-19 | $4.81M derived: sum of 3 quarters · filed 2026-03-19 | $1.12M 10-K · filed 2026-03-19 |
| 2024-09-30 | $1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.71M derived: sum of 2 quarters · filed 2025-11-10 | -$979.00K 10-Q · filed 2025-11-10 | $879.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $1.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$2.16M 10-Q · filed 2025-08-06 | -$299.00K derived: sum of 3 quarters · filed 2025-08-06 | -$601.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$3.69M 10-Q · filed 2025-05-08 | -$1.83M derived: sum of 2 quarters · filed 2025-05-08 | -$2.14M derived: sum of 3 quarters · filed 2025-05-08 | -$1.10M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $1.56M derived: sum of 2 quarters · filed 2025-03-20 | $2.59M derived: sum of 3 quarters · filed 2025-03-20 | -$1.57M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$302.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $732.00K derived: sum of 2 quarters · filed 2024-11-07 | -$3.43M 10-Q · filed 2024-11-07 | -$1.79M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$3.13M 10-Q · filed 2024-08-08 | -$1.49M derived: sum of 3 quarters · filed 2024-08-08 | -$537.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$4.16M 10-Q · filed 2024-05-08 | -$2.52M derived: sum of 2 quarters · filed 2024-05-08 | -$1.57M derived: sum of 3 quarters · filed 2024-05-08 | $662.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $2.59M derived: sum of 2 quarters · filed 2024-03-28 | $4.82M derived: sum of 3 quarters · filed 2024-03-28 | $458.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $950.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $3.18M derived: sum of 2 quarters · filed 2023-11-08 | -$1.18M 10-Q · filed 2023-11-08 | $238.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $2.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$2.13M 10-Q · filed 2023-08-09 | -$712.00K derived: sum of 3 quarters · filed 2023-08-09 | $447.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$4.37M 10-Q · filed 2023-05-04 | -$2.94M derived: sum of 2 quarters · filed 2023-05-04 | -$1.79M derived: sum of 3 quarters · filed 2023-05-04 | -$1.12M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $1.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $2.58M derived: sum of 2 quarters · filed 2023-03-22 | $3.24M derived: sum of 3 quarters · filed 2023-03-22 | -$5.07M 10-K · filed 2023-03-22 |
| 2021-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.82M derived: sum of 2 quarters · filed 2022-11-08 | -$6.49M 10-Q · filed 2022-11-08 | -$1.78M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $663.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$7.65M 10-Q · filed 2022-08-09 | -$2.94M derived: sum of 3 quarters · filed 2022-08-09 | -$1.40M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$8.31M 10-Q · filed 2022-05-12 | -$3.60M derived: sum of 2 quarters · filed 2022-05-12 | -$2.06M derived: sum of 3 quarters · filed 2022-05-12 | -$673.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $4.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $6.25M derived: sum of 2 quarters · filed 2022-03-11 | $7.64M derived: sum of 3 quarters · filed 2022-03-11 | $3.83M 10-K · filed 2022-03-11 |
| 2020-09-30 | $1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $2.93M derived: sum of 2 quarters · filed 2021-11-04 | -$877.00K 10-Q · filed 2021-11-04 | $2.14M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$2.42M 10-Q · filed 2021-08-05 | $600.00K derived: sum of 3 quarters · filed 2021-08-05 | $2.03M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$3.81M 10-Q · filed 2021-05-06 | -$792.00K derived: sum of 2 quarters · filed 2021-05-06 | $636.00K derived: sum of 3 quarters · filed 2021-05-06 | $887.00K derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $3.02M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $4.44M derived: sum of 2 quarters · filed 2021-02-25 | $4.70M derived: sum of 3 quarters · filed 2021-02-25 | $2.02M 10-K · filed 2021-02-25 |
| 2019-09-30 | $1.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.68M derived: sum of 2 quarters · filed 2020-11-05 | -$1.00M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $251.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$2.43M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | -$2.68M 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | $382.00K 10-K · filed 2021-02-25 | |||
| 2017-12-31 | $1.63M 10-K · filed 2020-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |